70 search results for: symposium

ADVENT at WCI
Congress
12
October
2025
Congress
ADVENT at WCI 2025

Join ADVENT for an educational symposium on PN at WCI 2025!

.
Congress
9
March
2024
Congress
The Benefits of Early Intervention in AD: More Than Skin Deep

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.

ADVENT at EAACI 2025
Congress
13
June
2025
Congress
ADVENT at EAACI 2025

Join Profs. Brian Lipworth, Zuzana Diamant, and Philippe Gevaert at an sponsored symposium about the latest strategies for the management of co-existing type 2 asthma and severe and/or uncontrolled CRSwNP.

Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice
Dermatology
Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice
expert video

This symposium highlights type 2 inflammation as a key driver of chronic itch and the characteristic skin lesions of prurigo nodularis and evaluates the real-world implications of targeted therapies on clinical practice.

View more
ADVENT at ERS-ISIAN 2025
Congress
20
June
2025
Congress
ADVENT at ERS-ISIAN 2025

Join experts Vibeke Backer, MD, DMSC, and Sietze Reitsma, MD, at an educational symposium involving a comprehensive exploration of the type 2 inflammation and its pivotal role in the pathogenesis and management of CRSwNP.

ADVENT at NAPNAP 2025
Congress
12
March
2025
Congress
ADVENT at NAPNAP 2025

Join experts Jonathan Spergel, MD, PhD, Wanda Phipatanakul, MD, MS, and Jerry Ellen Schonfeld, CPNP, at an educational symposium as they investigate the role of type 2 inflammation in pediatric diseases. The speakers will also discuss the difficulties in diagnosis and burdens patients and their families face.

Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation
Dermatology
Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation
expert video

This symposium delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid. It highlights both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies through a series of engaging panel discussions with Drs Eichenfield, Elmariah, Culton, and Hawkes.

View more
Etiology and Diagnosis of Bullous Pemphigoid
Dermatology
Etiology and Diagnosis of Bullous Pemphigoid
expert video

Professor Joost Meijer discusses the complex etiology and diagnosis of BP

View more
Factors Contributing to Diagnostic Delays in Bullous Pemphigoid
Dermatology
Factors Contributing to Diagnostic Delays in Bullous Pemphigoid
expert video

Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP

View more
Pathophysiology of Blister Formation in Bullous Pemphigoid
Dermatology
Pathophysiology of Blister Formation in Bullous Pemphigoid
expert video

Professor Enno Schmidt discusses the pathophysiology of BP, focusing on the role of type 2 inflammation and blister formation

View more
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in PN and CSU
Congress
11
March
2024
Congress
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in PN and CSU

Join Drs. Elmariah, Kim, and Metz as they explore the latest research on neuro-immune mechanisms driving chronic itch and inflammation in PN and CSU.

GUF PNG
Congress
4
December
2024
Congress
Translating the Science of CSU: From Pathogenesis to Patient Outcomes

Join Drs. Michihiro Hide, Marta Ferrrer, and Ana M. Giménez-Arnau as they discuss chronic spontaneous urticaria (CSU) and highlight the unmet needs, treatment challenges, and emerging therapies.